• No se han encontrado resultados

Diagnostic value of fibronectin discriminant score for predicting liver fibrosis stages in chronic hepatitis C virus patients

N/A
N/A
Protected

Academic year: 2020

Share "Diagnostic value of fibronectin discriminant score for predicting liver fibrosis stages in chronic hepatitis C virus patients"

Copied!
10
0
0

Texto completo

Loading

Figure

Table 1. Comparison between laboratory blood tests and Metavir fibrosis stages in estimation and validation groups
Table 3 presents the diagnostic performances of the investigated markers and combined markers at the optimal cutoff
Figure 4. ROC curves for fibronectin discriminant score (FDS) based on fibronectin, APRI and albumin in the estimation group

Referencias

Documento similar

(a) NPs@PEG in the liver, (b) NPs@Glc in the liver and (c) NPs@Glc in the spleen at different post-administration times (72 h and four months). If in the spleen the core of

The assessment of perceived health status in patients with chronic diseases is essential for measuring the impact and burden of disease, as in the case of patients with

In this study, internal tissues of chicken liver samples were analysed for the presence of phages using a meta- genomics approach and the liver virome was compared with that of

In our study, admitted COVID-19 patients with CLD and abnormal admission LFTs had higher median levels of D-dimer, which could be associated with major systemic inflammation and

When analyzed for its diagnostic value in this cohort of 9 patients and 10 controls, the levels of ANXA2 biomarker were found increased in complete plasma samples from

Several systems, molecules and responses involved in the pathogenesis of the pathological fibrosis of chronic kidney disease (CKD) will be discussed in this review, putting

This study evaluated the usefulness of baseline FibroScan values for predicting SVR and the occurrence of anemia and other severe adverse events in HCV genotype 1 patients with

Core tip: The Milan criteria for liver transplantation have improved survival of patients with small hepatocellular carcinoma (HCC), but up to 20% of patients still experience